Skip to main
DHR
DHR logo

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Danaher has demonstrated strong performance with performance obligations increasing to $4.9 billion in 2Q25, indicating solid demand and a healthy backlog from prior quarters. The company’s Life Sciences segment is projected to achieve a growth ramp of approximately 4.5% in 4Q25, supported by favorable comparisons in Genomics, robust performance in China, and strategic new product launches. Furthermore, the stability in book-to-bill ratios at around 1.0x highlights balance in order intake versus fulfillment, contributing to a positive outlook for Danaher's operational momentum.

Bears say

Danaher's outlook appears negative, as the percentage of obligations expected to be recognized as revenue within the next 12 months has decreased from 48% to 46%, indicating a potential slowdown in revenue recognition. Additionally, the company faces several risks that could further impede growth, including geopolitical disruptions, foreign exchange fluctuations, and the possibility that high-growth end-markets, particularly in China, do not recover as anticipated. Furthermore, revenue guidance for the Biotechnology and Life Sciences sector came in slightly below expectations, contributing to concerns regarding overall financial performance.

Danaher (DHR) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 20 analysts, Danaher (DHR) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $254.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $254.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.